It has been shown that FoxO3 may attenuate the idiopathic pulmonary fibrosis myofibroblast phenotype in vitro and bleomycin-induced lung fibrosis in vivo (Al-Tamari et al., 2018), prevent the progression of kidney diseases (Li et al., 2019; Lim et al., 2019) and promote kidney injury after UUO (Li L. et al., 2017). The gene discussed is FOXO3; the disease is kidney disorder.